Explore
Featured
Recent
Articles
Topics
Login
Upload
Featured
Recent
Articles
Topics
Login
Upload
Search Results for 'sof hcv'
sof hcv published presentations and documents on DocSlides.
SMV + DCV + SOF Open label
by summer
≥ 18 years. Chronic HCV infection. Genotype 1 or...
EASL 2019 HCV Conference Update
by sophia
April 10. –14. , 2019. Vienna, Austria. Disclaim...
Treatment of Chronic HCV
by lam
with Direct-Acting Antivirals (DAAs). www.hcvguide...
Simplified HCV Therapy in 2018
by phoebe-click
This program is s. upported. by educational gran...
SMV 150 mg QD SOF 400 mg QD
by alida-meadow
Randomisation. 1 : 1. 18-70 years. HCV genotype 1...
LDV/SOF
by conchita-marotz
Open-label. Chronic HCV infection. Genotype 1 . F...
SOF/VEL
by trish-goza
400/100 mg . qd. N = 120. N = 120. W12. SOF + RBV...
SOF/VEL
by lois-ondreau
400/100 mg . qd. N = 500. N = 100. W12. Placebo. ...
Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Patients With HCV Genotype 3 Infection:
by kittie-lecroy
Interim Analysis of a French Multicenter Compassi...
Daclatasvir in Combination With Sofosbuvir
by mitsue-stanley
With Or Without Ribavirin Is Safe and Efficacious...
Hepatitis C Drug Pipeline
by cheryl-pisano
HCV WORLD CAB . FEBRUARY 2014. BANGKOK, THAI...
Daclatasvir in Combination With Sofosbuvir
by mitsue-stanley
With Or Without Ribavirin Is Safe and Efficacious...
LDV/SOF 90/400 mg
by aaron
qd. Non-randomised. Open-label. N =. 21. W12. SV...
ALLY-2
by tawny-fly
Design. Objective. SVR. 12. (HCV RNA < 25 IU/...
ALLY-2
by aaron
Design. Objective. SVR. 12. (HCV RNA < 25 IU/...
ALLY-3 Design Objective SVR
by mitsue-stanley
12. (HCV RNA < 25 IU/ml), . with. 95% CI. DC...
Slides for today’s webinar are available on the CIHS website at:
by tatiana-dople
Slides for today’s webinar are available on the...
FISSION Design Objective
by travis
Non . inferiority. of SOF + RBV : SVR. 12. (. 2-...
Use of HCV DAAs with HIV Regimens
by robaut
Sam Lam, . PharmD. Annie Vong, . PharmD. 2/3/2017....
Prevention strategies for HIV/HCV co infection
by giovanna-bartolotta
Isabelle Andrieux-Meyer, MD. Médecins Sans Front...
HCV Clinical Management TRAINER(S)
by danika-pritchard
IAPAC African Regional Capacity-Building Hub. Bas...
Sofosbuvir-Velpatasvir in Decompensated HCV Cirrhosis
by ahmir
ASTRAL-4. Source: Curry MP, et al. N Engl J Med. 2...
HCV Clinical Management TRAINER(S)
by trish-goza
IAPAC African Regional Capacity-Building Hub. Bas...
Safety and Efficacy of Daclatasvir
by tabitha
. Plus . Sofosbuvir. With or Without Ribavirin . ...
Ledipasvir-Sofosbuvir ( Harvoni
by sherrill-nordquist
). Slide deck prepared . by: . David H. Spach, MD...
ION-4
by briana-ranney
Design. LDV/SOF. Open-label. ION-4 . Study. : LDV...
SMV 150 mg
by faustina-dinatale
qd. + SOF 400 mg . qd. N = 40. W12. 18-70 years....
SIRIUS
by tawny-fly
Placebo. LDV/SOF + placebo. Randomisation*. 1 : 1...
Use the Web Browser on Your Mobile Device to Participate in Polling*
by phoebe-click
Go to: pollev.com/CCO2. or scan the QR code below...
CURRY
by faustina-dinatale
Design. Open-label. CURRY . Study. : SOF + RBV fo...
HIV and HCV Update for the Pharmacist – June 2014
by marina-yarberry
John J. . Faragon. , . PharmD. , BCPS, AAHIV-P. R...
Out With the Old and In With the New, Again?
by test
Out With the Old, In With the New. Current Standa...
Are Pan-Genotypic Therapies Ready for Prime Time?
by lois-ondreau
3. Rd. International . HIV/Hepatitis . Coinfecti...
Ledipasvir-Sofosbuvir (
by lindy-dunigan
Harvoni. ). Prepared by: . David H. Spach, MD and...
Community Pharmacy Considerations for HIV
by tawny-fly
& HCV . Therapy. Larry Pineda, . PharmD. , . ...
Hepatitis C: A New Era In Treatment And Cure
by myesha-ticknor
Adam . Deising. , DO. LCDR MC USN. Director of . ...
Updated Guidelines for Managing HIV/HCV Co-Infection
by karlyn-bohler
John J . Faragon. , . PharmD. , BCPS, AAHIV-P. Re...
NIAID ERADICATE
by tatiana-dople
Open-label. W12. ≥ 18 years. Chronic HCV infect...
Simeprevir
by olivia-moreira
. + Sofosbuvir +/- Ribavirin in Genotype 1. COS...
Load More...
